Popular on TelAve


Similar on TelAve

Adherix Health launches SMS-first retention platform for GLP-1 treatment programs

TelAve News/10897217
Behavioral engagement system targets the critical 90-day dropout window with phase-based outreach and automated trigger logic

CHARLOTTE, N.C. - TelAve -- Adherix Health today announced the public launch of its behavioral retention platform, purpose-built for clinics managing GLP-1 treatment programs. The platform delivers phase-based SMS engagement, automated patient trigger logic, and Drift Correction technology designed to identify at-risk patients before they go silent and disengage.

GLP-1 medications have demonstrated strong clinical efficacy, but data consistently shows 40 to 60 percent of patients discontinue treatment within the first year - with the majority of dropout concentrated in the first 90 days, during dose titration when side effects peak and the gap between clinical appointments is longest. For clinic operators, each lost patient represents both a clinical failure and a measurable revenue loss averaging $600 per patient per month.

"Clinics are doing everything right clinically but losing patients in the gap between appointments," said Sean Johnson, founder of Adherix Health. "We built Adherix to fill that gap with structured, behavior-driven outreach that does not require a single additional staff hour."

More on TelAve News
The Adherix platform (https://adherixhealth.com/platform) organizes every patient journey into six progression phases - from initiation through long-term maintenance - and evaluates behavioral signals across the full patient population at 60-second intervals. When a patient shows early signs of disengagement, the system fires targeted SMS interventions automatically. When a patient goes silent for five days, clinic staff receive an escalation alert before the patient fully churns.

Key platform capabilities include:
  • Phase-based SMS progression across six treatment stages, from day one through maintenance
  • Trigger-driven outreach for non-response, plateau risk, and dose adherence gaps
  • Drift Correction - a pattern-detection layer that identifies four behavioral drift signals and queues locked-copy correction messages with a 72-hour cooldown per patient
  • Injection confirmation tracking with weekly adherence measurement and missed-dose escalation
  • HIPAA-aware infrastructure with Business Associate Agreement support for covered deployments
  • Deployment in under five minutes - no EMR integration or IT resources required

The platform is live at adherixhealth.com. Adherix Health is currently accepting applications from metabolic care clinics for its founding partner program (https://adherixhealth.com/pilot).

More on TelAve News
About Adherix Health

Adherix Health is a behavioral retention platform purpose-built for GLP-1 treatment programs. The platform delivers phase-based SMS engagement, automated trigger logic, and real-time Drift Correction to help metabolic care clinics identify at-risk patients early and sustain adherence through the critical first 90 days of treatment. Adherix operates as a Business Associate under HIPAA and is designed for clinic operators who need a lightweight, auditable outreach layer without adding staff overhead. Learn more at adherixhealth.com.

Media contact Sean Johnson, founder Adherix Health press@adherixhealth.com adherixhealth.com

Source: Adherix Health

Show All News | Disclaimer | Report Violation

0 Comments

Latest on TelAve News